65,437 trials
Graft-Versus-Host Disease (GVHD) Acute on Chronic
Primary: Number (Percentage) of Patients at Each Dosing Cohort Who Experience no Toxicity and in Whom Graft Versus Host Disease (GVHD) is Stable or Improved — 6; 2; 2 Participants
Chronic Kidney Disease · End Stage Renal Disease
Primary: Total EPO Secretion — 24.1 U/Kg/d
Breast Cancer
Primary: Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus…
Cataract · Phacoemulsification Cataract Surgery
Primary: Percentage of Cellularity in Anterior Chamber — 64.2; 64.3; 0; 0 Percentage of Cellularity — p=1.00
Type 2 Diabetes
Primary: Differences in Glycemic Control — 171; 159; 126; 132 mg/dl
Hypoglycemia · Complications of Bariatric Procedures
Primary: Detection/Notification of Hypoglycemia — 9 successful events
Follicular Lymphoma
Primary: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 — 70.7; 75.5 percentage of participants
Sleep Disorders
Primary: Total Sleep Time (TST) — 51.03; 18.71 minutes — p==0.035
Male Hypogonadism
Primary: Absolute Change From Baseline in T Cholesterol — 0.2; 8.2 mg/dL
NSAID · Pain Management
Primary: Visual Analog Scale (VAS) Pain Scores at 6 Hours After Treatment — 0.6; 2.6; 1.0; 2.0 scores on a scale — p=0.04
Chronic Obstructive Pulmonary Disease
Primary: Unpleasantness of Breathlessness — 69.0; 71.1 units on a scale
Healthy Participants
Primary: Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021 — 48100 nanogram*hours per milliliter (ng*h/mL)
Femoral Arteriotomy Closure
Primary: Major Complications — 0; 0 Participants
Malaria
Primary: Number of Participants With Adverse Events — 4; 5; 5; 6 Participants
Acute Decompensated Heart Failure
Primary: Percentage of Participants With Health Care Utilizations — 28.6 percentage of participants